The malignant pleural mesothelioma market is poised for steady growth during the forecast period (2025–2034). The launch of innovative therapies by companies such as AstraZeneca, Polaris ...

The role of surgery for malignant pleural mesothelioma encompasses the need for rapid diagnosis, preoperative staging and surgical resection of this rare and aggressive malignancy.

Malignant pleural mesothelioma is the most common type, with about 70 percent of mesothelioma diagnoses. Another 15 percent to 20 percent of diagnoses are for peritoneal mesothelioma, ...

Malignant mesothelioma is a rare asbestos-associated malignancy with limited therapeutic options. Despite advances in the treatment, the median survival remains 12 months from the time of diagnosis.

Of the 38 patients with malignant pleural mesothelioma at our institution in this pandemic era, seven were diagnosed with COVID-19 infection (18%) by a positive RT-PCR." ...

Malignant pleural mesothelioma is an aggressive tumor associated with asbestos exposure. Malignant pleural mesothelioma was once a rare disease, but its incidence is increasing worldwide and ...

Malignant pleural mesothelioma is a rare malignancy that has been strongly linked to asbestos exposure, and an estimated 3,000 people are diagnosed with the disease in the United States annually.

Malignant pleural mesothelioma is divided into three subtypes, one of which is particularly aggressive. Researchers from the Comprehensive Cancer Center (CCC) of MedUni Vienna and Vienna General ...

As for safety, the most common adverse reactions reported with nivolumab plus ipilimumab in patients with malignant pleural mesothelioma were fatigue, musculoskeletal pain, rash, dyspnea, nausea ...

The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.

Purpose The etiology, diagnosis, staging, and management of malignant pleural mesothelioma (MPM) are reviewed, with an emphasis on clinical trials of newer approaches to first-line, second-line ...